Stockscreener 앱 받기
0.7455
1.24%
-0.0038
전일 마감가:
$0.7493
열려 있는:
$0.7569
하루 거래량:
39,086
Relative Volume:
0.10
시가총액:
$31.47M
수익:
$2.93M
순이익/손실:
$-25.30M
주가수익비율:
-1.3901
EPS:
-0.5363
순현금흐름:
$-33.59M
1주 성능:
-5.96%
1개월 성능:
-2.25%
6개월 성능:
-11.92%
1년 성능:
-23.71%
1일 변동 폭
$0.73
$0.7569
1주일 범위
$0.6961
$0.8101
52주 변동 폭
$0.565
$1.31
Scynexis Inc Stock (SCYX) Company Profile
명칭
Scynexis Inc
전화
201-884-5485
주소
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.75 | 31.47M | 2.93M | -25.30M | -33.59M | -0.5363 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.84 | 59.23B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.99 | 55.34B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.49 | 49.30B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.13 | 39.43B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
493.80 | 21.70B | 3.13B | 1.27B | 1.12B | 26.39 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-01-22 | 개시 | Guggenheim | Buy |
| 2021-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-11 | 업그레이드 | Needham | Hold → Buy |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-10 | 개시 | ROTH Capital | Buy |
| 2017-05-09 | 다운그레이드 | Needham | Buy → Hold |
| 2017-03-03 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-20 | 개시 | H.C. Wainwright | Buy |
| 2016-10-07 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2016-08-17 | 개시 | Guggenheim | Buy |
| 2016-08-09 | 재확인 | Needham | Buy |
| 2016-08-09 | 업그레이드 | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | 개시 | Brean Capital | Buy |
| 2015-12-29 | 개시 | WBB Securities | Speculative Buy |
| 2015-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2015-06-10 | 개시 | Needham | Buy |
| 2014-05-29 | 개시 | Canaccord Genuity | Buy |
| 2014-05-29 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Scynexis Inc 주식(SCYX)의 최신 뉴스
Does SCYNEXIS Inc. align with a passive investing strategyTrade Entry Report & Expert-Curated Trade Recommendations - mfd.ru
Short Squeeze: Will SCYNEXIS Inc benefit from rate cutsJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Can SCYNEXIS Inc. expand into new marketsWeekly Risk Report & Consistent Growth Equity Picks - mfd.ru
Market Moves: Is SCYNEXIS Inc backed by strong institutional buyingQuarterly Portfolio Report & AI Forecast Swing Trade Picks - baoquankhu1.vn
Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period (2025-2034) | DelveInsight - The Malaysian Reserve
FOMO Trade: Does SCYNEXIS Inc have pricing powerJuly 2025 Levels & Community Driven Trade Alerts - baoquankhu1.vn
Swing Trade: Is SCYNEXIS Inc backed by strong institutional buyingMarket Performance Summary & Weekly Consistent Profit Watchlists - baoquankhu1.vn
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting - marketscreener.com
Scynexis (SCYX) to Present Data on Advanced Antifungal Drug at K - GuruFocus
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) - The Manila Times
New antifungal SCY-247 shows potent activity against deadly drug-resistant fungi - stocktitan.net
Companies Like SCYNEXIS (NASDAQ:SCYX) Could Be Quite Risky - Sahm
Aug Macro: Can SCYNEXIS Inc expand into new marketsQuarterly Earnings Summary & Safe Entry Trade Reports - baoquankhu1.vn
JERSEY CITYFDA grants fast track and QIDP designations to SCYNEXIS drug - Investing.com Nigeria
Scynexis (SCYX) Gains FDA Designations for Antifungal Therapy SC - GuruFocus
Scynexis receives FDA qualified infectious disease product and fast track designations for SCY-247 - marketscreener.com
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 - The Manila Times
FDA fast-tracks new antifungal aimed at deadly Candida auris infections - Stock Titan
Breakout Move: Is SCYNEXIS Inc benefiting from innovation trendsMarket Sentiment Review & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Aug Volume: Is SCYNEXIS Inc stock trending bullishWeekly Trade Analysis & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
FEDERATED HERMES, INC. Acquires Additional Shares in SCYNEXIS Inc. - GuruFocus
Retail Trends: Can SCYNEXIS Inc expand into new marketsWeekly Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
RSI Check: Is SCYNEXIS Inc benefiting from innovation trendsWeekly Trend Report & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Jobs Data: Will SCYNEXIS Inc stock continue dividend increasesJuly 2025 Levels & Community Driven Trade Alerts - Bộ Nội Vụ
Published on: 2026-01-11 17:42:44 - Улправда
SCYNEXIS halts phase 3 MARIO trial, raising new questions for ibrexafungerp’s growth path - MSN
Why SCYNEXIS Inc. (135A) stock is listed among top recommendationsJobs Report & Low Risk Investment Opportunities - ulpravda.ru
Why hedge funds are buying SCYNEXIS Inc. stockWeekly Trade Summary & AI Driven Price Predictions - Улправда
Gains Report: Does SCYNEXIS Inc stock trade at a discount to peersWeekly Trade Recap & Expert Curated Trade Ideas - Bộ Nội Vụ
How SCYNEXIS Inc. stock compares to industry benchmarksOptions Play & Daily Stock Momentum Reports - Улправда
Why SCYNEXIS Inc. stock is trending among retail tradersResistance Breakout Alerts & Free Rapid Return Acceleration - bollywoodhelpline.com
Portfolio Update: How SCYNEXIS Inc stock compares to industry benchmarksJuly 2025 Highlights & Free Safe Capital Growth Stock Tips - moha.gov.vn
SCYNEXIS granted Nasdaq extension to regain bid price compliance - MSN
What analysts say about SCYNEXIS Inc 135A stockFundamental Strength Indicators & Build Wealth With Expert Timing Advice - earlytimes.in
Scynexis receives 180-day extension from Nasdaq to meet listing requirements - Investing.com
Scynexis granted 180-day extension by Nasdaq to regain compliance with minimum bid price requirement - marketscreener.com
SCYNEXIS, Inc. Receives 180-Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Quiver Quantitative
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - The Manila Times
Earnings Report: Why SCYNEXIS Inc. stock is trending among retail tradersAnalyst Downgrade & Long Hold Capital Preservation Plans - Улправда
SCYNEXIS Earnings Notes - Trefis
Is SCYNEXIS Inc. stock trading at a premium valuationEarnings Risk Summary & Reliable Volume Spike Alerts - Улправда
Shorts Report: How SCYNEXIS Inc. (135A) stock compares with tech leadersEarnings Summary Report & Safe Entry Momentum Stock Tips - moha.gov.vn
SCYNEXIS Halts Phase 3 MARIO Trial, Raising New Questions for Ibrexafungerp’s Growth Path - TipRanks
Will SCYNEXIS Inc. stock deliver better than expected guidance2025 Key Lessons & Advanced Swing Trade Entry Plans - DonanımHaber
Can SCYNEXIS Inc. stock continue upward trendEarnings Summary Report & Long-Term Growth Stock Strategies - Улправда
How SCYNEXIS Inc. (135A) stock compares with tech leadersJuly 2025 Momentum & Verified Stock Trade Ideas - Bölüm Sonu Canavarı
Why SCYNEXIS Inc. stock is a must watch in 2025Market Trend Review & Fast Momentum Stock Entry Tips - Улправда
Nasdaq Moves: Why SCYNEXIS Inc. stock is a must watch in 2025Weekly Stock Recap & AI Powered Market Trend Analysis - Улправда
Is SCYNEXIS Inc. stock a contrarian buy2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - ulpravda.ru
What insider purchases suggest about SCYNEXIS Inc. (135A) stockJuly 2025 Macro Moves & AI Enhanced Trading Alerts - ulpravda.ru
Scynexis Inc (SCYX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.91%
자본화:
|
볼륨(24시간):